Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.43 |
| ▸ | CDA | P32320 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11665141 | 0.85 | MAPT (0.48) | PYGMCDAMAPTSLC28A1SLC28A2 | |
| SCHEMBL5975040 | 0.79 | PYGM (0.49) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL9060322 | 0.76 | PYGM (0.49) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL9064907 | 0.76 | PYGM (0.49) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL4432028 | 0.76 | SLC28A1 (0.48) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL2056570 | 0.75 | SLC28A1 (0.47) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL8536800 | 0.74 | PYGM (0.46) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL22408740 | 0.74 | LMNA (0.47) | PYGMCDAMAPTSLC28A1SLC28A2 | |
| SCHEMBL8536802 | 0.74 | PYGM (0.46) | PYGMCDAMAPTTK2SLC28A1 | |
| SCHEMBL8538141 | 0.74 | PYGM (0.46) | PYGMCDAMAPTTK2SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | claimed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2003-05-29 | — | — | US | claimed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | claimed |
| EP-1261339-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | Pharmacia Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| JP-2002536407-A | — | — | 2002-10-29 | — | — | JP | claimed |
| JP-2002502875-A | — | — | 2002-01-29 | — | — | JP | claimed |
| EP-1173161-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-23 | — | — | EP | claimed |
| EP-1165080-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001008672-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2001-02-08 | — | — | WO | claimed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | claimed |
| WO-2000047198-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-08-17 | — | — | WO | claimed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | claimed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | PYGM 464/4885CDA 260/4885MAPT 4163/4885 |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | HAVCR2, DERA, GALE | PYGM 640/4885CDA 59/4885MAPT 4546/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | PYGM 1537/4885CDA 1661/4885MAPT 4525/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | PYGM 772/4885CDA 90/4885MAPT 4664/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | PYGM 425/4885CDA 79/4885MAPT 4728/4885 |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | IMPDH1, HAVCR2, IMPDH2 | PYGM 1396/4885CDA 59/4885MAPT 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.